Avenacy Launches Dehydrated Alcohol Injection, USP in Unique 5-Vial Pack in the U.S.

Avenacy Announces Launch of USP Vials

Avenacy is a top pharmaceutical corporation concentrated on the provision of serious injectable medicines, declared the launch of Dehydrated Alcohol Injection, USP in the United States. It is used as a relaxing generic equivalent of Ablysinol®, which finished its market exclusiveness in June 2025. Dehydrated Alcohol Injection is shown to encourage skillful cardiac septal infarction to expand exercise potential in adults with indicative hypertrophic obstructive cardiomyopathy who are not candidates for medical myectomy.

Each ampoule of Dehydrated Alcohol Injection comprises a volume of 5 mL of ethyl alcohol ≥99% and is provided in a carton of almost five single-dose vials. Avenacy is presently the only provider in the U.S. contributing this invention in a 5-pack arrangement, as long as healthcare services with superior flexibility in monitoring inventory expenses.

In line with Avenacy’s assignment to Victor, patient security and rationalize patient care, Dehydrated Alcohol Injection will feature the Corporation’s extremely distinguished packing and labeling to funding correct medication choice.

Avenacy will begin shipping Dehydrated Alcohol Injection, USP, to wholesale partners this week. The Corporation is maintained by a worldwide system of expansion and agreement engineering partners that have experienced successful FDA examinations based on cGMP values.

• Dehydrated Alcohol Injection, USP had U.S. sales of about $71 million for the twelve months ended in March 2025.

Avenacy is a U.S.-founded specialty pharmaceutical industry concentrated on providing critical injectable medicines utilized to treat patients in several medically managed situations, from acute care hospitals to outpatient physician offices and clinics. Through a rigorous and enhanced selection process, the corporation is constructing a pipeline of superior-quality, FDA-approved injectable products to safeguard a strong portfolio that can fulfill the requirements of a dynamic drug supply chain. With a skilled team, a promise to excellence and dependability, and invention designed to enable safe and effective patient care, Avenacy endeavors to be an important partner for crucial medications.

Jeff Yordon, Co-Founder and CEO of Avenacy, expressed,

“As we continue to add to our rapidly growing portfolio, the launch of Dehydrated Alcohol Injection reflects our strategy of entering high-value markets with practical, differentiated solutions. The vial format of Avenacy’s product supports safe handling, and the unique 5-pack presentation helps providers manage high-cost inventory more efficiently, reflecting our company’s longstanding commitment to providing products that meet the needs of both patients and healthcare providers.”